指南与共识支持与姑息治疗

ASCO免疫检查点抑制剂治疗相关不良事件管理指南

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.
指南 / 共识 · J Clin Oncol · 2018-02-14

该指南由ASCO召集多学科专家组制定,基于2000至2017年文献的系统综述(纳入204篇合格出版物),针对免疫检查点抑制剂(ICPi)治疗相关不良事件提供按器官系统分类的诊断与管理推荐。因高质量证据缺乏,推荐主要基于专家共识;总体原则包括1级毒性继续ICPi并密切监测、2级毒性可暂停并对症处理、3级毒性暂停并起始大剂量皮质类固醇、4级毒性一般永久停用。

要点

  • 1级毒性一般继续ICPi并密切监测,但某些神经、血液和心脏毒性例外。
  • 2级毒性可暂停ICPi,症状恢复至1级或以下时可考虑重启,可给予皮质类固醇。
  • 3级毒性一般暂停ICPi并起始大剂量皮质类固醇(泼尼松1-2 mg/kg/d或甲泼尼龙1-2 mg/kg/d),至少4-6周内逐渐减量;难治性病例可能需要英夫利西单抗或其他免疫抑制治疗。

核心结论

  • ICPi相关不良事件的管理因受累器官系统而异,总体按毒性分级决定ICPi继续、暂停或永久停用及皮质类固醇使用。

研究设计与样本

  • 多学科、多组织专家小组制定临床实践指南,系统综述聚焦2000至2017年发表的指南、系统综述与荟萃分析、随机对照试验和病例系列,共纳入204篇合格出版物。

主要发现

  • 证据多来自观察性数据的系统综述、共识指南、病例系列和病例报告,高质量证据缺乏。
  • 推荐按特定器官系统毒性诊断与管理分别呈现。

关键数值与推荐

  • 1级毒性:一般继续ICPi并密切监测,但某些神经、血液和心脏毒性例外。
  • 2级毒性:可暂停ICPi,症状恢复至1级或以下时可考虑重启,可给予皮质类固醇。
  • 3级毒性:一般暂停ICPi并起始大剂量皮质类固醇(泼尼松1-2 mg/kg/d或甲泼尼龙1-2 mg/kg/d),至少4-6周内逐渐减量;难治性病例可能需要英夫利西单抗或其他免疫抑制治疗。
  • 4级毒性:一般推荐永久停用ICPi,但经激素替代控制的內分泌病除外。

临床怎么用

  • 临床应依据毒性分级和受累器官系统,参照指南推荐决定ICPi的继续、暂停或永久停用,并规范使用皮质类固醇及免疫抑制治疗。

局限性

  • 因高质量证据缺乏,推荐主要基于专家共识。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events in patients treated with immune checkpoint inhibitor (ICPi) therapy. Methods A multidisciplinary, multi-organizational panel of experts in medical oncology, dermatology, gastroenterology, rheumatology, pulmonology, endocrinology, urology, neurology, hematology, emergency medicine, nursing, trialist, and advocacy was convened to develop the clinical practice guideline. Guideline development involved a systematic review of the literature and an informal consensus process. The systematic review focused on guidelines, systematic reviews and meta-analyses, randomized controlled trials, and case series published from 2000 through 2017. Results The systematic review identified 204 eligible publications. Much of the evidence consisted of systematic reviews of observational data, consensus guidelines, case series, and case reports. Due to the paucity of high-quality evidence on management of immune-related adverse events, recommendations are based on expert consensus. Recommendations Recommendations for specific organ system-based toxicity diagnosis and management are presented. While management varies according to organ system affected, in general, ICPi therapy should be continued with close monitoring for grade 1 toxicities, with the exception of some neurologic, hematologic, and cardiac toxicities. ICPi therapy may be suspended for most grade 2 toxicities, with consideration of resuming when symptoms revert to grade 1 or less. Corticosteroids may be administered. Grade 3 toxicities generally warrant suspension of ICPis and the initiation of high-dose corticosteroids (prednisone 1 to 2 mg/kg/d or methylprednisolone 1 to 2 mg/kg/d). Corticosteroids should be tapered over the course of at least 4 to 6 weeks. Some refractory cases may require infliximab or other immunosuppressive therapy. In general, permanent discontinuation of ICPis is recommended with grade 4 toxicities, with the exception of endocrinopathies that have been controlled by hormone replacement. Additional information is available at www.asco.org/supportive-care-guidelines and www.asco.org/guidelineswiki .

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018. PMID: 29442540. doi:10.1200/JCO.2017.77.6385

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。